The Eyes Still Have It For Novartis Despite Sell-Off Rumors
Some Ophthalmology Assets Reported To Be Up For Grabs
Rumors have resurfaced that Novartis is looking to shift some of its eye drugs but the Basle-based behemoth tells Scrip it remains committed to in-market products and R&D projects in the ophthalmology space.
You may also be interested in...
Sandoz CEO Saynor Talks Spinoff, Leadership And Place Among Peers
In the first part of an exclusive three-part interview, Sandoz CEO Richard Saynor talks to Generics Bulletin about the firm’s upcoming separation from parent company Novartis, as well as outlining its unique position as a pure generics and biosimilars company among an evolving peer group of off-patent industry leaders.
Roche Clinical Lead Labels Lucentis Biosimilars ‘Pandora’s Box’
Eight months after biosimilar competition to Roche’s Lucentis (ranibizumab) emerged in the US, ophthalmologists and doctors remain confused about how to incorporate them into their practice, a clinical trial lead representing the Swiss originator has proffered.
Novartis Sneaks Ahead Of Sanofi To Buy Gyroscope
The Swiss giant is paying up to $1.5bn upfront to get hold of Gyroscope's AAV2-based one-time investigational gene therapy for geographic atrophy, an advanced form of dry AMD that leads to irreversible vision loss.